NAACCR Item #3862: JAK2
| Item # | Length | Source of Standard | Year Implemented | Version Implemented | Year Retired | Version Retired |
|---|---|---|---|---|---|---|
| 3,862 | 1 | NAACCR |
NAACCR XML: Tumor.jak2
Description
Janus Kinase 2 (JAK2, JAK 2) is a gene mutation that increases susceptibility to several myeloproliferative neoplasms (MPNs). Testing for the JAK2 mutation is done on whole blood. Nearly all people with polycythemia vera, and about half of those with primary myelofibrosis and essential thrombocythemia, have the mutation. JAK2 analysis continues to increase in use for hematopoietic neoplasms.
Rationale
JAK2 can be collected by the surveillance community for myeloproliferative neoplasms. Prior to 2018, HemeRetic SSF#1 was used for JAK2.
Codes
| 0 | JAK2 result stated as negative |
| 1 | JAK2 positive for mutation V617F WITH or WITHOUT other mutations |
| 2 | JAK2 positive for exon 12 mutation |
| 3 | JAK2 positive for other specified mutation |
| 4 | JAK2 positive for more than one mutation other than V617F |
| 5 | JAK2 positive NOS Specific mutation(s) not stated |
| 7 | Test ordered, results not in chart |
| 8 | Not applicable: Information not collected for this case (If this item is required by your standard setter, use of code 8 will result in an edit error.) |
| 9 | Not documented in medical record JAK2 not assessed or unknown if assessed |
Each Site-Specific Data Item (SSDI) applies only to selected primary sites, histologies, and years of diagnosis. Depending on applicability and standard-setter requirements, SSDIs may be left blank.